![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » NITROMED, INC. REVISES SALES AND MARKETING STRATEGY; CUTS 120 JOBS
NITROMED, INC. REVISES SALES AND MARKETING STRATEGY; CUTS 120 JOBS
NitroMed, Inc. announced a revision of its strategy and business model in a move intended to focus its resources on the accelerated development of an extended release formulation of BiDil (isosorbide dinitrate/hydralazine hydrochloride), known as BiDil XR. This alternative strategy employs a less costly approach to marketing the current immediate release formulation of BiDil during BiDil XR's development that includes significantly reduced direct sales efforts. BioSpace (http://www.biospace.com/news_story.aspx?StoryID=32712&full=1)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct